©The Author(s) 2022.
World J Hepatol. Feb 27, 2022; 14(2): 338-353
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.338
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.338
Table 3 Uses of available cytomegalovirus assays
| Use | Assay |
| Diagnosis | CMV viral load by plasma QNAT; CMV viral load by real-time PCR assay; pp65 antigen testing; CMV IgG/IgM antibodies |
| Diagnosis of tissue-invasive CMV disease | Histopathology |
| Pre-transplant risk stratification | CMV IgG/IgM antibodies |
| Threshold for initiation of pre-emptive therapy | CMV viral load by plasma QNAT; Quantitative pp65 antigen measurement; NASBA assay |
| Monitoring or endpoint (prophylaxis, pre-emptive or treatment) | CMV viral load by plasma QNAT; QuantiFERON-CMV assay |
| Endpoint of treatment of tissue-invasive CMV disease | Histopathology |
| Prediction of developing CMV disease | QuantiFERON-CMV assay |
- Citation: Onpoaree N, Sanpavat A, Sintusek P. Cytomegalovirus infection in liver-transplanted children. World J Hepatol 2022; 14(2): 338-353
- URL: https://www.wjgnet.com/1948-5182/full/v14/i2/338.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i2.338